BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Fiche publication
Date publication
septembre 2020
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALAC Sophie
Tous les auteurs :
Frazao A, Rethacker L, Jeudy G, Colombo M, Pasmant E, Avril MF, Toubert A, Moins-Teisserenc H, Roelens M, Dalac S, Maubec E, Caignard A
Lien Pubmed
Résumé
Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine-threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a mutation. However, acquired resistance occurs in the majority of patients, leading to relapse. Immunotherapies that activate immune cytotoxic effectors induce long-lasting responses in 30% of patients. In that context, combination of targeted therapies with immunotherapy (IT) is a promising approach. We considered boosting natural killer (NK) cell tumor immunosurveillance, as melanoma cells express stress-induced molecules and activate NK cell lysis.
Mots clés
cellular, combination, drug therapy, immunity, immunotherapy, killer cells, melanoma, natural
Référence
J Immunother Cancer. 2020 Sep;8(2):